GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » E10

Actinium Pharmaceuticals (Actinium Pharmaceuticals) E10 : $-8.76 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Actinium Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.310. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-8.76 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 24.40% per year. During the past 5 years, the average E10 Growth Rate was 16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Actinium Pharmaceuticals was 24.40% per year. The lowest was -4.50% per year. And the median was -1.30% per year.

As of today (2024-05-01), Actinium Pharmaceuticals's current stock price is $7.78. Actinium Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-8.76. Actinium Pharmaceuticals's Shiller PE Ratio of today is .


Actinium Pharmaceuticals E10 Historical Data

The historical data trend for Actinium Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals E10 Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.35 -26.20 -26.33 -12.55 -11.30

Actinium Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.69 -12.38 -12.30 -11.30 -8.76

Competitive Comparison of Actinium Pharmaceuticals's E10

For the Biotechnology subindustry, Actinium Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Shiller PE Ratio falls into.



Actinium Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Actinium Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.31/129.4194*129.4194
=-0.310

Current CPI (Mar. 2024) = 129.4194.

Actinium Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 3.000 100.560 3.861
201409 -6.300 100.428 -8.119
201412 -5.100 99.070 -6.662
201503 -2.700 99.621 -3.508
201506 -6.000 100.684 -7.712
201509 -3.000 100.392 -3.867
201512 -4.800 99.792 -6.225
201603 -3.000 100.470 -3.864
201606 -4.200 101.688 -5.345
201609 -4.200 101.861 -5.336
201612 -3.600 101.863 -4.574
201703 -4.200 102.862 -5.284
201706 -3.600 103.349 -4.508
201709 -2.700 104.136 -3.356
201712 -1.800 104.011 -2.240
201803 -2.100 105.290 -2.581
201806 -1.200 106.317 -1.461
201809 -1.800 106.507 -2.187
201812 -1.500 105.998 -1.831
201903 -1.500 107.251 -1.810
201906 -0.999 108.070 -1.196
201909 -1.210 108.329 -1.446
201912 -0.800 108.420 -0.955
202003 -0.980 108.902 -1.165
202006 -0.410 108.767 -0.488
202009 -0.360 109.815 -0.424
202012 -0.370 109.897 -0.436
202103 -0.290 111.754 -0.336
202106 -0.250 114.631 -0.282
202109 -0.300 115.734 -0.335
202112 -0.360 117.630 -0.396
202203 -0.230 121.301 -0.245
202206 -0.330 125.017 -0.342
202209 -0.380 125.227 -0.393
202212 -0.430 125.222 -0.444
202303 -0.430 127.348 -0.437
202306 -0.580 128.729 -0.583
202309 -0.490 129.860 -0.488
202312 -0.330 129.419 -0.330
202403 -0.310 129.419 -0.310

Add all the adjusted EPS together and divide 10 will get our e10.


Actinium Pharmaceuticals  (AMEX:ATNM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Actinium Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals (Actinium Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
275 Madison Avenue, 7th Floor, New York, NY, USA, 10016
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Executives
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin officer: VP, Finance and Corporate Dev. 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig officer: Chief Scientific Officer 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell director 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty director 643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur officer: Chief Commercial Officer 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray officer: Executive Vice President 14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center 10 percent owner 1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa director 138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave director, officer: President and CEO 4 WATER STREET, EDISON NJ 08820
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc 10 percent owner C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd. 10 percent owner C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000

Actinium Pharmaceuticals (Actinium Pharmaceuticals) Headlines

From GuruFocus